Cargando…
RIPK1-Induced A1 Reactive Astrocytes in Brain in MPTP-Treated Murine Model of Parkinson’s Disease
Neuroinflammation is one of the hallmarks of Parkinson’s disease, including the massive activation of microglia and astrocytes and the release of inflammatory factors. Receptor-interacting protein kinase 1 (RIPK1) is reported to mediate cell death and inflammatory signaling, and is markedly elevated...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216483/ https://www.ncbi.nlm.nih.gov/pubmed/37239205 http://dx.doi.org/10.3390/brainsci13050733 |
_version_ | 1785048308985626624 |
---|---|
author | Qiao, Chenmeng Niu, Guyu Zhao, Weijiang Quan, Wei Zhou, Yu Zhang, Meixuan Li, Ting Zhou, Shengyang Huang, Wenyan Zhao, Liping Wu, Jian Cui, Chun Shen, Yanqin |
author_facet | Qiao, Chenmeng Niu, Guyu Zhao, Weijiang Quan, Wei Zhou, Yu Zhang, Meixuan Li, Ting Zhou, Shengyang Huang, Wenyan Zhao, Liping Wu, Jian Cui, Chun Shen, Yanqin |
author_sort | Qiao, Chenmeng |
collection | PubMed |
description | Neuroinflammation is one of the hallmarks of Parkinson’s disease, including the massive activation of microglia and astrocytes and the release of inflammatory factors. Receptor-interacting protein kinase 1 (RIPK1) is reported to mediate cell death and inflammatory signaling, and is markedly elevated in the brain in PD mouse models. Here, we aim to explore the role of RIPK1 in regulating the neuroinflammation of PD. C57BL/6J mice were intraperitoneally injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 20 mg/kg four times/day), followed by necrostatin-1 treatment (Nec-1, RIPK1 inhibitor; 1.65 mg/kg once daily for seven days. Notably, the first Nec-1 was given 12 h before MPTP modeling). Behavioral tests indicated that inhibition of RIPK1 greatly relieved motor dysfunction and anxiety-like behaviors of PD mice. It also increased striatal TH expression, rescue the loss of dopaminergic neurons, and reduce activation of astrocytes in the striatum of PD mice. Furthermore, inhibition of RIPK1 expression reduced A1 astrocytes’ relative gene expression (CFB, H2-T23) and inflammatory cytokine or chemokine production (CCL2, TNF-α, IL-1β) in the striatum of PD mice. Collectively, inhibition of RIPK1 expression can provide neuroprotection to PD mice, probably through inhibition of the astrocyte A1 phenotype, and thus RIPK1 might be an important target in PD treatment. |
format | Online Article Text |
id | pubmed-10216483 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102164832023-05-27 RIPK1-Induced A1 Reactive Astrocytes in Brain in MPTP-Treated Murine Model of Parkinson’s Disease Qiao, Chenmeng Niu, Guyu Zhao, Weijiang Quan, Wei Zhou, Yu Zhang, Meixuan Li, Ting Zhou, Shengyang Huang, Wenyan Zhao, Liping Wu, Jian Cui, Chun Shen, Yanqin Brain Sci Article Neuroinflammation is one of the hallmarks of Parkinson’s disease, including the massive activation of microglia and astrocytes and the release of inflammatory factors. Receptor-interacting protein kinase 1 (RIPK1) is reported to mediate cell death and inflammatory signaling, and is markedly elevated in the brain in PD mouse models. Here, we aim to explore the role of RIPK1 in regulating the neuroinflammation of PD. C57BL/6J mice were intraperitoneally injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 20 mg/kg four times/day), followed by necrostatin-1 treatment (Nec-1, RIPK1 inhibitor; 1.65 mg/kg once daily for seven days. Notably, the first Nec-1 was given 12 h before MPTP modeling). Behavioral tests indicated that inhibition of RIPK1 greatly relieved motor dysfunction and anxiety-like behaviors of PD mice. It also increased striatal TH expression, rescue the loss of dopaminergic neurons, and reduce activation of astrocytes in the striatum of PD mice. Furthermore, inhibition of RIPK1 expression reduced A1 astrocytes’ relative gene expression (CFB, H2-T23) and inflammatory cytokine or chemokine production (CCL2, TNF-α, IL-1β) in the striatum of PD mice. Collectively, inhibition of RIPK1 expression can provide neuroprotection to PD mice, probably through inhibition of the astrocyte A1 phenotype, and thus RIPK1 might be an important target in PD treatment. MDPI 2023-04-27 /pmc/articles/PMC10216483/ /pubmed/37239205 http://dx.doi.org/10.3390/brainsci13050733 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Qiao, Chenmeng Niu, Guyu Zhao, Weijiang Quan, Wei Zhou, Yu Zhang, Meixuan Li, Ting Zhou, Shengyang Huang, Wenyan Zhao, Liping Wu, Jian Cui, Chun Shen, Yanqin RIPK1-Induced A1 Reactive Astrocytes in Brain in MPTP-Treated Murine Model of Parkinson’s Disease |
title | RIPK1-Induced A1 Reactive Astrocytes in Brain in MPTP-Treated Murine Model of Parkinson’s Disease |
title_full | RIPK1-Induced A1 Reactive Astrocytes in Brain in MPTP-Treated Murine Model of Parkinson’s Disease |
title_fullStr | RIPK1-Induced A1 Reactive Astrocytes in Brain in MPTP-Treated Murine Model of Parkinson’s Disease |
title_full_unstemmed | RIPK1-Induced A1 Reactive Astrocytes in Brain in MPTP-Treated Murine Model of Parkinson’s Disease |
title_short | RIPK1-Induced A1 Reactive Astrocytes in Brain in MPTP-Treated Murine Model of Parkinson’s Disease |
title_sort | ripk1-induced a1 reactive astrocytes in brain in mptp-treated murine model of parkinson’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216483/ https://www.ncbi.nlm.nih.gov/pubmed/37239205 http://dx.doi.org/10.3390/brainsci13050733 |
work_keys_str_mv | AT qiaochenmeng ripk1induceda1reactiveastrocytesinbraininmptptreatedmurinemodelofparkinsonsdisease AT niuguyu ripk1induceda1reactiveastrocytesinbraininmptptreatedmurinemodelofparkinsonsdisease AT zhaoweijiang ripk1induceda1reactiveastrocytesinbraininmptptreatedmurinemodelofparkinsonsdisease AT quanwei ripk1induceda1reactiveastrocytesinbraininmptptreatedmurinemodelofparkinsonsdisease AT zhouyu ripk1induceda1reactiveastrocytesinbraininmptptreatedmurinemodelofparkinsonsdisease AT zhangmeixuan ripk1induceda1reactiveastrocytesinbraininmptptreatedmurinemodelofparkinsonsdisease AT liting ripk1induceda1reactiveastrocytesinbraininmptptreatedmurinemodelofparkinsonsdisease AT zhoushengyang ripk1induceda1reactiveastrocytesinbraininmptptreatedmurinemodelofparkinsonsdisease AT huangwenyan ripk1induceda1reactiveastrocytesinbraininmptptreatedmurinemodelofparkinsonsdisease AT zhaoliping ripk1induceda1reactiveastrocytesinbraininmptptreatedmurinemodelofparkinsonsdisease AT wujian ripk1induceda1reactiveastrocytesinbraininmptptreatedmurinemodelofparkinsonsdisease AT cuichun ripk1induceda1reactiveastrocytesinbraininmptptreatedmurinemodelofparkinsonsdisease AT shenyanqin ripk1induceda1reactiveastrocytesinbraininmptptreatedmurinemodelofparkinsonsdisease |